Home›Stock Screener›Crop Life Science›Financial Statements

Crop Life Science Complete Financial Statements

4 Years of Data
2026 - 2023

In FYNone, Crop Life Science (CLSL) reported revenue ₹0 Cr, net profit ₹0 Cr and EPS ₹0.00, with a net profit margin of 2.9% and ROE of 7.1%. Full financial statements from FY2023 to FY2026 (4 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Analyse CLSL institutional holdings to track promoter, FII and institutional holdings.

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 2.90% 2026 data
EBITDA Margin 8.70% 2026 data
Operating Margin 9.00% 2026 data
Return on Assets 2.88% 2026 data
Return on Equity 7.14% 2026 data

Balance Sheet Ratios

Current Ratio 29.50 2026 data
Equity Ratio 40.38% 2026 data
Asset Turnover 1.00 2026 data

CLSL Revenue, Net Profit & EBITDA — Year-on-Year Growth

CLSL YoY (March 2026 vs Period) — revenue -100.0%, net profit -100.0%, EBITDA -100.0%, expenses -100.0%. For live price, earnings ratios and company overview, see Crop Life Science screener.

Revenue Growth
-100.0%
Year-over-Year
Net Profit Growth
-100.0%
Year-over-Year
EBITDA Growth
-100.0%
Year-over-Year
Expense Growth
-100.0%
Year-over-Year
Assets Growth
+14.3%
Year-over-Year
Equity Growth
+3.7%
Year-over-Year
Operating Cash Flow Growth
+75.0%
Year-over-Year
Investing Cash Flow Growth
-33.3%
Year-over-Year
Financing Cash Flow Growth
-69.2%
Year-over-Year

CLSL Income Statement — Revenue, EBITDA & Net Profit

Crop Life Science revenue ₹0 Cr, EBITDA ₹0 Cr, net profit ₹0 Cr, EPS ₹0.00 (None) — net profit margin 2.9%. Also explore CLSL share price charts to track price trends across different timeframes.

Periods ₹ Crores
Particulars None March 2026 March 2025 March 2024 March 2023
Revenue 0 207 202 201 132
Expenses 0 189 184 186 120
EBITDA 0 18 17 15 13
Operating Profit Margin % 0.00% 9.00% 8.00% 6.00% 9.00%
Depreciation 0 5 5 3 4
Interest 0 5 5 3 3
Profit Before Tax 0 9 8 8 6
Tax 0 3 2 2 2
Net Profit 0 6 6 6 4
Earnings Per Share (₹) 0.00 3.79 3.27 3.54 3.39

CLSL Balance Sheet — Assets, Liabilities & Shareholders' Equity

CLSL total assets ₹208 Cr, total equity ₹84 Cr, total liabilities ₹ Cr (2026) — ROE 7.1%.

Years Annual Data ₹ Crores
Particulars 2026 2025 2024 2023
ASSETS
Total Assets 208 182 180 102
Current Assets 177 142 140 86
Fixed Assets 28 38 39 16
Capital Work in Progress 0 0 0 0
Investments 71 1 0 0
Other Assets 0 143 141 86
LIABILITIES
Total Liabilities
Current Liabilities 6 8 11 6
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 84 81 76 41
Share Capital 17 17 17 12
Reserves & Surplus 67 60 55 29

CLSL Cash Flow Statement — Operating, Investing & Financing

Crop Life Science operating cash flow ₹-2 Cr, investing ₹-4 Cr, financing ₹4 Cr, net cash flow ₹-1 Cr (2025).

Periods ₹ Crores
Particulars March 2025 March 2024 March 2023
Operating Activities -2 -8 2
Investing Activities -4 -3 -5
Financing Activities 4 13 1
Net Cash Flow -1 2 -2